NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners (“Forbion”), one of the leading Dutch venture capital firms investing in world-class healthcare technologies, announces that its portfolio company, Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs to treat dyslipidemic patients suffering from cardiovascular disease (CVD), will be acquired by Amgen, Inc. (NASDAQ: AMGN). Amgen has agreed to acquire all outstanding shares of Dezima for up to US$1.55b